GSL Synthetase Inhibitor or in Combination With Immune Checkpoint Inhibitor in Previously Treated Blood and Solid Tumor
Status:
Recruiting
Trial end date:
2023-06-01
Target enrollment:
Participant gender:
Summary
Immune checkpoint blockade has made great but unsatisfied success in treating cancers. One
important reason is the hijacked HLA-I antigen presentation. Eliglustat could inhibit
glycosphingolipids synthesis and restore HLA-I antigen presentation and transform the
immunogenicity of tumor cells. Therefore,GSL synthetase inhibitor eliglustat monotherapy or
in combination with immune checkpoint inhibitor may explore a new avenue for therapeutic
intervention in cancer.